Graybug Vision’s pipeline products cover major eye indications that might lead to blindness, including neovascular (wet) age-related macular degeneration (nAMD), glaucoma, and corneal graft rejection. The lead product, GB-102, contains a single small molecule compound that inhibits multiple pathogenic angiogenesis pathways known to be involved in the choroidal neovascularization, the cause of nAMD.
In clinical studies of nAMD, blockage of the vascular endothelial growth factor (VEGF) and platelet derived growth factor-beta (PDGF) angiogenesis pathways together has been shown to be more effective than blockage of a single pathway. GB-102 is designed to provide the benefits of current multi-product therapies as a single dose administration with as few injections as twice per year. Graybug Vision is also evaluating a proprietary library of compounds that have both intraocular pressure (IOP) lowering and neuroprotection. Once the lead compound has been selected, Graybug Vision intends to develop an every 6 month subconjunctival injection product using its proprietary ocular delivery technologies. In addition, proof of concept in an animal model has been demonstrated with a Graybug Vision product designed to treat corneal graft rejection.